Nykredit A S Purchases Shares of 254,719 Kenvue Inc. $KVUE

Nykredit A S bought a new stake in Kenvue Inc. (NYSE:KVUE) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 254,719 shares of the company’s stock, valued at approximately $4,868,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in KVUE. CoreCap Advisors LLC grew its holdings in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after acquiring an additional 591 shares during the period. Montag A & Associates Inc. grew its stake in Kenvue by 6.3% in the 1st quarter. Montag A & Associates Inc. now owns 10,156 shares of the company’s stock valued at $175,000 after acquiring an additional 600 shares during the period. Cornerstone Wealth Group LLC increased its stake in shares of Kenvue by 5.9% during the first quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company’s stock worth $187,000 after purchasing an additional 606 shares in the last quarter. Mill Creek Capital Advisors LLC increased its stake in Kenvue by 0.6% during the 4th quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock worth $2,143,000 after buying an additional 701 shares in the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management raised its stake in Kenvue by 0.3% in the 4th quarter. B & T Capital Management DBA Alpha Capital Management now owns 234,664 shares of the company’s stock valued at $4,048,000 after purchasing an additional 712 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Down 0.2%

Kenvue stock opened at $18.70 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $20.69. The stock has a 50-day simple moving average of $19.19 and a 200-day simple moving average of $18.26. The company has a market capitalization of $35.92 billion, a P/E ratio of 21.49, a PEG ratio of 1.67 and a beta of 0.46.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The business had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.97 billion. During the same quarter last year, the business posted $0.29 earnings per share. The business’s revenue was up 3.0% on a year-over-year basis. Equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th were issued a dividend of $0.21 per share. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a dividend yield of 4.5%. The ex-dividend date of this dividend was Wednesday, August 12th. Kenvue’s dividend payout ratio is 96.55%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on KVUE. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Barclays boosted their target price on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. UBS Group reduced their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Finally, Zacks Research cut Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.